Noninvasive imaging signatures of HER2 and HR using ADC in invasive breast cancer: repeatability, reproducibility, and association with pathological complete response to neoadjuvant chemotherapy

Table 1 Patients characteristics in discovery and validation cohort

Variable	Discovery cohort		Validation cohort		P value
Total, N	117		74
Age
Mean (range)	49.03 (25–77)		48.58 (27–72)		0.769
Race					0.414
White	87	74.35%	53	71.62%
Asian	10	8.55%	3	4.05%
Black	9	7.69%	9	12.16%
Unknown	11	9.41%	8	10.81%
Native Hawaiian or other Pacific Islander	0	0	1	1.35%
Lesion type					0.309
Multiple masses	65	55.56%	33	44.59%
Multiple NME	5	4.27%	6	8.11%
Single mass	43	36.75%	30	40.54%
Single NME	4	3.42%	5	6.76%
HER2					0.974
Positive	30	25.64%	18	24.32%
Negative	87	74.36%	56	75.68%
HR					0.959
Positive	71	60.68%	46	62.16%
Negative	46	39.32%	28	37.84%
SBR grade					0.592
I (Low)	3	2.56%	2	2.70%
II (Intermediate)	36	30.77%	17	22.97%
III (High)	77	65.81%	55	74.32%
Unknown	1	0.85%	0	0
MRLD
Mean (range)	4.02 (0.44–15)		4.73 (1.6–13.2)		0.049
pCR					1.000
pCR	36	30.77%	23	31.08%
non-pCR	81	69.23%	51	68.92%
Treatment arm*					0.351
Paclitaxel	23	19.66%	15	20.27%
Paclitaxel + Trastuzumab	3	2.56%	1	1.35%
Paclitaxel + MK-2206	11	9.40%	6	8.11%
Paclitaxel + Trastuzumab + MK-2206	9	7.69%	2	2.70%
Paclitaxel + Trebananib	27	23.08%	12	16.22%
Paclitaxel + Trastuzumab + Trebananib	2	1.71%	4	5.41%
Trastuzumab + Pertuzumab	10	8.55%	4	5.41%
Paclitaxel + Trastuzumab + Pertuzumab	6	5.13%	4	5.41%
Paclitaxel + Ganitumab	24	20.51%	20	27.03%
Paclitaxel + Ganetespib	2	1.71%	3	4.05%
Paclitaxel + Neratinib	0	0	2	2.70%
Unknown	0	0	1	1.35%

NME, non-mass-like enhancement; HR, hormone receptor; HER2, human epidermal growth factor receptor 2; SBR, grade Scarff-Bloom-Richardson grade; MRLD, MRI measured longest diameter (cm) at baseline (T0) study; pCR, pathologic complete response; MK-2206, AKT inhibitor
*All treatment arms are followed by 4 cycles of doxorubicin/cyclophosphamide

ISSN: 1465-542X